UML Specification and Transformation of Safety Features for Memory Protection

AbstractDeferasirox (DFX) is the newest among three different chelators available to treat iron overload in iron-loading anaemias, firstly released as Dispersible Tablets (DT) and more recently replaced by Film-Coated Tablets (FCT). In this retrospective observational study, pharmacokinetics, pharmacodynamics, and safety features of DFX treatment were analyzed in 74 patients that took both formulations subsequently under clinical practice conditions. Bioavailability of DFX FCT compared to DT resulted higher than expected [Cmax: 99.5 (FCT) and 69.7 (DT) μMol/L; AUC: 1278 (FCT) and 846 (DT), P < 0.0001]. DFX FCT was also superior in scalability among doses. After one year of treatment for each formulation, no differences were observed between the treatments in the overall iron overload levels; however, DFX FCT but not DT showed a significant dose–response correlation [Spearman r (dose-serum ferritin variation): − 0.54, P < 0.0001]. Despite being administered at different dosages, the long-term safety profile was not different between formulations: a significant increase in renal impairment risk was observed for both treatments and it was reversible under strict monitoring (P < 0.002). Altogether, these data constitute a comprehensive comparison of DFX formulations in thalassaemia and other iron-loading anaemias, confirming the effectiveness and safety characteristics of DFX and its applicability for treatment tailoring.

Download Full-text

Self-shutdown function induced by sandwich-like gel polymer electrolytes for high safety lithium metal batteries

RSC Advances ◽

10.1039/d1ra02641k ◽

2021 ◽

Vol 11 (23) ◽

pp. 14036-14046

Author(s):

Binxuan Xie ◽

Shimou Chen ◽

Yong Chen ◽

Lili Liu

Keyword(s):

Polymer Electrolytes ◽

High Performance ◽

Gel Polymer Electrolytes ◽

Lithium Metal ◽

Lithium Metal Batteries ◽

Safety Features

The SGPE can achieve high performance and high safety features simultaneously.

Download Full-text

Automatic Roadway Features Detection with Oriented Object Detection

Applied Sciences ◽

10.3390/app11083531 ◽

2021 ◽

Vol 11 (8) ◽

pp. 3531

Author(s):

Hesham M. Eraqi ◽

Karim Soliman ◽

Dalia Said ◽

Omar R. Elezaby ◽

Mohamed N. Moustafa ◽

...

Keyword(s):

Object Detection ◽

Safety Evaluation ◽

Autonomous Driving ◽

Detection Accuracy ◽

The Road ◽

Detection Model ◽

Detection Approach ◽

Roadway Safety ◽

Safety Features ◽

Oriented Object

Extensive research efforts have been devoted to identify and improve roadway features that impact safety. Maintaining roadway safety features relies on costly manual operations of regular road surveying and data analysis. This paper introduces an automatic roadway safety features detection approach, which harnesses the potential of artificial intelligence (AI) computer vision to make the process more efficient and less costly. Given a front-facing camera and a global positioning system (GPS) sensor, the proposed system automatically evaluates ten roadway safety features. The system is composed of an oriented (or rotated) object detection model, which solves an orientation encoding discontinuity problem to improve detection accuracy, and a rule-based roadway safety evaluation module. To train and validate the proposed model, a fully-annotated dataset for roadway safety features extraction was collected covering 473 km of roads. The proposed method baseline results are found encouraging when compared to the state-of-the-art models. Different oriented object detection strategies are presented and discussed, and the developed model resulted in improving the mean average precision (mAP) by 16.9% when compared with the literature. The roadway safety feature average prediction accuracy is 84.39% and ranges between 91.11% and 63.12%. The introduced model can pervasively enable/disable autonomous driving (AD) based on safety features of the road; and empower connected vehicles (CV) to send and receive estimated safety features, alerting drivers about black spots or relatively less-safe segments or roads.

Download Full-text

Scalable Pointer-based Memory Protection for Data-intensive Computing

2020 International Conference on Information and Communication Technology Convergence (ICTC) ◽

10.1109/ictc49870.2020.9289601 ◽

2020 ◽

Author(s):

Baik Song An

Keyword(s):

Data Intensive Computing ◽

Data Intensive ◽

Memory Protection

Download Full-text

Use of Topiramate in the Spectrum of Addictive and Eating Disorders: A Systematic Review Comparing Treatment Schemes, Efficacy, and Safety Features

CNS Drugs ◽

10.1007/s40263-020-00780-y ◽

2021 ◽

Vol 35 (2) ◽

pp. 177-213

Author(s):

Mikail Nourredine ◽

Lucie Jurek ◽

Bernard Angerville ◽

Yannick Longuet ◽

Julia de Ternay ◽

...

Keyword(s):

Systematic Review ◽

Eating Disorders ◽

Efficacy And Safety ◽

Safety Features

Download Full-text

Lantox—The Chinese Botulinum Toxin Drug—Complete English Bibliography and Comprehensive Formalised Literature Review

Toxins ◽

10.3390/toxins13060370 ◽

2021 ◽

Vol 13 (6) ◽

pp. 370

Author(s):

Dirk Dressler ◽

Lizhen Pan ◽

Junhui Su ◽

Fei Teng ◽

Lingjing Jin

Keyword(s):

Literature Review ◽

Observational Studies ◽

Similar Efficacy ◽

Conversion Ratio ◽

Brand Names ◽

Efficacy And Safety ◽

Paper Citation ◽

Safety Features ◽

Randomised Controlled ◽

Nose And Throat

In 1997, lanbotulinumtoxinA (LAN) was introduced in China. It is now available in Asia, Latin America and Eastern Europe under various brand names including Hengli®, Lantox®, Prosigne®, Lanzox®, Redux®, Liftox®, HBTX-A and CBTX-A. The literature on LAN is mostly published in Chinese language, restricting its international accessibility. We, therefore, wanted to generate a complete English bibliography of all LAN publications and then use it for a comprehensive formalised literature review. Altogether, 379 LAN publications (322 in Chinese and 57 in English) were retrieved from PubMed and Science and Technology Paper Citation Database. Indications covered are motor (257), glandular (16), pain (32) and aesthetics (48). Topics are neurological (250), aesthetic (48), paediatric (38), ophthalmological (18), urological (9), methodological (6), gastroenterological (5), ear, nose and throat (4) and surgical (1). Seventy-one publications are randomised controlled trials, forty-one publications are interventional studies and observational studies, fifteen publications are case studies, eighteen publications are reviews, and two publications are guidelines. LAN publications cover all relevant topics of BT therapy throughout a period of more than 20 years. This constitutes a publication basis resembling those of other BT drugs. None of the LAN publications presents data contradictory to those generated with other BT type-A drugs. LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 1:1 LAN– onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN’s registrations in Europe and North America.

Download Full-text